Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates
28/2 23:35
Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items....